Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

1. Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
   Pooled it
2. Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.JAMA neurology · 2026
   Trial
3. Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.ACS omega · 2025
   Review
4. Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal.Current neuropharmacology · 2025
   Review
5. Subthalamic Deep Brain Stimulation in Parkinson's Disease: A Boon or Bane - A Single Centre Retrospective Observational Study from India.Asian journal of neurosurgery · 2023
   Article
6. Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.Journal of Parkinson's disease · 2022
   Article
7. Urinary Tract Infection in Parkinson's Disease.Journal of Parkinson's disease · 2022
   Review
8. Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons.Tissue engineering. Part A · 2020
   Article
9. Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019
   Review
10. Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.Molecular neurobiology · 2018
    Article
11. Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.Therapeutic advances in neurological disorders · 2018
    Review
12. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model.Nature biotechnology · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract